具有组织病理学验证的 FAPi PET/CT 在各种癌症患者中的前瞻性探索性研究 (FAPI PET RDRC)
68Ga-FAPI-46 在不同恶性肿瘤患者中的 PET 生物分布研究:具有组织病理学验证的探索性生物分布研究
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To define the biodistribution of gallium Ga 68 fibroblast activation protein inhibitor (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with various malignancies.
SECONDARY OBJECTIVES:
I. To evaluate the degree of 68Ga-FAPi-46 accumulation observed by positron emission tomography (PET) imaging as opposed to the amount of FAP in excised cancer tissue.
II. To assess the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution and to define the frequency of the following phenotypes (FAP+/ FDG+, FAP-/ FDG+, FAP+/ FDG-, FAP-/ FDG-)
EXPERIMENTAL OBJECTIVE:
To assess the correlation of 68Ga-FAPI-46 biodistribution with 68Ga-DOTATATE or 18F-DOPA (FDOPA), depending on the specific indication in patients who had them available
OUTLINE:
Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- UCLA / Jonsson Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients with the following cancer types:
- Brain cancer
- Bladder cancer
- Urothelial cancer
- Testicular cancer
- Skin cancer
- Thyroid cancer
- Hepatocellular carcinoma
- Cholangiocarcinoma
- Thymus cancer
- Pleural cancer
- Cervical cancer
- Adrenal cancer
- Neuroendocrine tumors
- Hematologic cancer
- Cancer of Unkown Primary
-
Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
-
Patients are ≥ 18 years old at the time of the radiotracer administration.
-
Patient can provide written informed consent
-
Patient is able to remain still for duration of imaging procedure (up to one hour)
Exclusion Criteria:
- Patient is pregnant or nursing
- Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Basic science (68GA-FAPI-46 PET/CT)
Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable). |
Undergo PET/CT
其他名称:
Undergo PET/CT
其他名称:
Given IV
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues
大体时间:At 20-90 minutes after injection]
|
Will be quantified by mean and maximum standardized uptake values (SUVmean and SUVmax). |
At 20-90 minutes after injection]
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
68Ga-FAPi-46 accumulation observed by positron emission tomography (PET)/computed tomography (CT)
大体时间:Up to year 2
|
Will be correlated with FAP expression in surgically removed or biopsy derived tumor tissue. |
Up to year 2
|
|
68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution
大体时间:up to 2 years
|
2. To assess the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution and to define the frequency of the following phenotypes (FAP+/ FDG+, FAP-/ FDG+, FAP+/ FDG-, FAP-/ FDG-) |
up to 2 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To assess the 68Ga-FAPI-46 biodistribution correlation with other PET tracers
大体时间:60 minutes after tracer injection
|
The other PET tracer biodistribution will be described by mean and maximum standardized uptake values (SUVmean and SUVmax). The SUV of FAPI PET and the other PET tracers will be tested for correlation. |
60 minutes after tracer injection
|
合作者和调查者
调查人员
- 首席研究员:Jeremie Calais、UCLA / Jonsson Comprehensive Cancer Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 脑部疾病
- 中枢神经系统疾病
- 神经系统疾病
- 病理过程
- 生殖器肿瘤,男性
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 生殖器疾病,男性
- 男性泌尿生殖系统疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 组织学类型的肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 子宫疾病
- 生殖器疾病,女性
- 血液病
- 内分泌腺肿瘤
- 头颈肿瘤
- 肝病
- 肿瘤、腺体和上皮
- 腺癌
- 肝脏肿瘤
- 胸部肿瘤
- 肿瘤过程
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 淋巴系统疾病
- 泌尿系肿瘤
- 癌
- 宫颈疾病
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 神经系统肿瘤
- 子宫肿瘤
- 肾上腺疾病
- 中枢神经系统肿瘤
- 膀胱疾病
- 甲状腺疾病
- 肿瘤转移
- 睾丸疾病
- 病理状况、体征和症状
- 皮肤和结缔组织疾病
- 半身和淋巴疾病
- 癌,肝细胞癌
- 血液肿瘤
- 宫颈肿瘤
- 胆管癌
- 神经内分泌肿瘤
- 膀胱肿瘤
- 脑肿瘤
- 癌,移行细胞
- 皮肤肿瘤
- 胸腺肿瘤
- 原发性未知的肿瘤
- 甲状腺肿瘤
- 肾上腺肿瘤
- 睾丸肿瘤
- 调查技术
- 碳水化合物
- 化学技术,分析
- 频谱分析
- 脱氧葡萄糖
- 脱氧糖
- FAPI-46
- 氟脱氧葡萄糖F18
- 磁共振光谱
其他研究编号
- 20-000630
- NCI-2020-03766 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.